Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00944385

Enrollment

Unknown

Registered

2009-07-23

Start date

2009-06-30

Completion date

2011-04-30

Last updated

2011-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abnormal Aortic Valve

Brief summary

According to TEG (thromboelastography), as maximum amplitude is increased the amount of bleeding and transfusion and Cardiac enzyme is reduced by using ulinastatin.

Interventions

DRUGulinastatin

Administer 30000U/ulinastatin. Comparison of different dosages of drug.

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

* 40% below of output of left ventricle * tricuspid valve failure from moderate to severe * urgent surgery required * infectious endocarditis

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026